MétaCan
Menu
← Back to cohort

Ex-Vivo Gene Therapy Approach for Continuous Delivery of BDNF and Its Potential Use for Neurological Disorders (P02.013)

2012· article· en· W2086212500 on OpenAlexaff
A. Gomez-Vargas, G. Hortelano, M. Rathbone

Bibliographic record

VenueNeurology · 2012
Typearticle
Languageen
FieldNeuroscience
TopicNerve injury and regeneration
Canadian institutionsMcMaster University
Fundersnot available
KeywordsNeurotrophic factorsGene deliveryNeurotrophinBrain-derived neurotrophic factorGenetic enhancementMedicineNeuroprotectionPharmacologyIn vivoHippocampusBiologyInternal medicineReceptorGeneBiotechnology

Abstract

fetched live from OpenAlex

Objective: Evaluating persistent delivery of BDNF by gene therapy. Background Brain-derived neurotrophic factor (BDNF) potently prevents neuronal death and stimulate neuronal function. BDNF gene delivery to the entorhinal cortex ameliorated neuronal death, improved hippocampus-dependent memory AD. Similarly it supports the survival of nigral dopaminergic neurons in Parkinson9s disease. BDNF is a neuroprotective agent when administered within hours of ischaemia, enhancing axonal sprouting and synaptic function. Unfortunately its use is hampered by short-half life, limited biodistribution and limited bioavailability. Thus, the ideal system for BDNF administration must achieve effective concentrations at sites of degenerating neurons and delivery must be sustained. Design/Methods: G8 primary mouse myoblasts were transfected with a plasmid containing the cDNA for human bdnf. In order to prevent allograft rejections, genetically engineered myoblasts expressing human BDNF cells were encapsulated within alginate-PLL microcapsules with a molecular cut-off size of 300KDa, thus permeable to bdnf (27KDa). C57BL/6 mice (n=3) were implanted intraperitoneally, each mouse with approximately 9 x 106 recombinant BDNF-secreting myoblasts. Levels of BDNF expression in vivo and in vitro were measured by ELISA. Clinical evaluation and histological analysis were performed to evaluate side effects. Results: Transgene expression of BDNF by engineered myoblasts was verified by ELISA. Engineered myoblasts produced human BDNF at a rate of 430pg/106 cells/day. Mice were bled on day 0, 3 and 7. There were low but detectable levels of bdnf in plasma of treated mice suggesting its persistent bioavailability BDNF is known to cross the blood-brain barrier. Histopathological analysis disclosed no side effects. Conclusions: The remarkable potency of growth factors in preventing cell death and stimulating cell function in CNS disease provides incentive for this research. Encapsulated recombinant myoblast expressing BDNF overcome problems of dosing, administration and sustained bioavailability that might have a substantial impact in neurological diseases. This therapeutic approach will be evaluated in degenerative conditions like AD. Disclosure: Dr. Gomez-Vargas has nothing to disclose. Dr. Hortelano has nothing to disclose. Dr. Rathbone has received research support from Sanofi-Aventis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.048
GPT teacher head0.261
Teacher spread0.213 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueNeurology→Same topicNerve injury and regeneration→French-language works237,207→